Hypoalbuminemia as a Predictive Biomarker of Dyspnea Response to Dexamethasone and Placebo in Patients With Cancer: Secondary Analysis of the ABCD Randomized Clinical Trial

JCO Precision Oncology · Published 2026-07-01 · DOI 10.1200/po-26-00208

Authors (4)

David Hui, Kristofer Jennings, Amy Ontai, Eduardo Bruera

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Hui, D., Jennings, K., Ontai, A., et al. (2026). Hypoalbuminemia as a Predictive Biomarker of Dyspnea Response to Dexamethasone and Placebo in Patients With Cancer: Secondary Analysis of the ABCD Randomized Clinical Trial. JCO Precision Oncology. https://doi.org/10.1200/po-26-00208

Related articles

• Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study · JCO Precision Oncology · 2026 · Same journal
• Integrated Radioproteomic Modeling for Early Recurrence Prediction and Metabolic Characterization in Hepatocellular Carcinoma · JCO Precision Oncology · 2026 · Same journal
• Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials · JCO Precision Oncology · 2026 · Same journal
• Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study · JCO Precision Oncology · 2026 · Same journal
• Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I · JCO Precision Oncology · 2026 · Same journal
• DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers · JCO Precision Oncology · 2026 · Same journal
• Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis · JCO Precision Oncology · 2026 · Same journal
• Personalized Molecular Monitoring of a Cryptic DIAPH1::PDGFRB Fusion in Chronic Eosinophilic Leukemia Using Droplet Digital Polymerase Chain Reaction · JCO Precision Oncology · 2026 · Same journal
• Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma · JCO Precision Oncology · 2026 · Same journal
• Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020) · JCO Precision Oncology · 2026 · Same journal